1. DOP85 Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study. (27th May 2021) Authors: Vavricka, S R; Greuter, T; Cohen, B L; Reinisch, W; Steinwurz, F; Fellmann, M; Guo, X; Lawendy, N; Paulissen, J; Peyrin-Biroulet, L Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open. (21st January 2022) Authors: Biedermann, L; Dubinsky, M C; Vermeire, S; Fellmann, M; Gardiner, S; Hur, P; Mundayat, R; Panés, J; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P465 Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. (30th January 2023) Authors: Armuzzi, A; Rubin, D T; Schreiber, S; Panés, J; Fellmann, M; Bartolome, L; Goetsch, M; Bhattacharjee, A; Wu, J; Chaparro, M; Dubinsky, M C Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i593 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P607 Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open. (21st January 2022) Authors: Rubin, D T; Vavricka, S R; Armuzzi, A; Dubinsky, M C; Sharara, A I; Modesto, I; Fellmann, M; Liguori, G; Lawendy, N; Cadatal, M J; Lichtenstein, G R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i538 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗